Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I was lucky to pick some up on sale this morning in pre-market.
Should be a good buying opportunity early today.
Looks like a bit of a pull back day here today.
You just need to let this all sort out. Just forget about it for six months then come back and check out what happened here. It will be fine.
Let me give you a very good example of another trade:
Back in late 2007 I had SIRI at entry level of $1.67
They merged with XM radio and the share price fell like a lead weight. All the way down to .06 by Feb 2008.
I believed in the company just like I do with NAVB so I bought 200,000 more shares and averaged my price way down.
I later sold above $3 for a HUGE profit.
It just takes time and some intestinal fortitude!
I have been accumulating NAVB shares for the same reason.
It will eventually be in the $5 to $6 range.
Just MHO!
GLTU
There was tremendous price fluctuation again near the close. It's just incredible to see the manipulation going on here.
I agree the company appears very solid and they just happen to be the victim of forces beyond their control when it comes to share price.
Regardless though, the true price will eventually reflect itself here. I see the shorts continuing to burn shares in their efforts to keep the lid on, but once we get revenues coming in this quarter, the short squeeze will be of historic proportions!
I see days like today as awesome buying opportunities.
I ordered my first Lymphoseek scan on a patient today.
The hospitals in my area are starting to order.
This will be huge in another couple of quarters!
The 6 analysts offering 12-month price forecasts for Navidea Biopharmaceuticals Inc have a median target of 5.50, with a high estimate of 9.00 and a low estimate of 1.50. The median estimate represents a +131.09% increase from the last price of 2.38.
I like the price action the past few days!
Technically, we own units in the partnership and not really shares so when a div. is paid, you get a check based on net revenues.
This is not a multiple of earnings like when you buy and sell shares.
It is awesome owning a small piece of this refining company.
The sp should be near $38 by Sept.
GLTA
Lol!
Yes. Dropped $1.58 exactly because we get the div.
You can track the current share price if you like by simply adding 1.58 to what it is currently trading for.
The current price reflects the $1.58
So buying this AM at 33.19 is really just like buying yesterday at 34.77
There is no difference in price.
The 1.58 gets paid out to folks holding units.
I bought them in my IRA account so the tax is automatically deferred
Lol,
Believe what your DD tells you my friend.
I bought ACAD for $1.50 last summer
F for 4.95 couple of years ago
SIRI for .06 in 2007
Not that long ago. All of those were undervalued when I bought as well.
This one will do the same as those IMO.
I believe the payout is May 17 at 1.58 per unit.
It came out this AM pre-market and will go to share holders of record on May 10th
I agree with you that it should be a great summer hold!
BTW: I doubt JPM would buy shares just because NAVB needed cash.
JPM is in the business of making money, so their analysts obviously feel that NAVB is a good investment as well.
The point you are trying to make against NAVB is actually in their favor.
GLTU
I disagree as do most analysts who have a price target around $5
They have plenty of cash to support not only operations but also the ongoing development of their pipeline agents.
The conference call was truly, very positive.
The reason the stock price has not climbed is because of pure manipulation by the shorties.
GLTU as you are obviously short on NAVB, but it's a stiff current you are trying to swim against!
Great buying opportunity today on the small dip!
More great news!
The company continues on target and should increase from here as we begin to see revenues coming in in the second quarter from Lymphoseek sales.
The pipeline looks very promising indeed, and Cardinal will insure that it gets the job done!
I'm buying more today on the dip!
Great earnings. We should continue to set new highs in the coming quarter.
I believe it is foolish and kind of sad to see folks selling this morning in the $33's when the share price drop is just a reflection of the 18.18% dividend coming out this AM.
Payable to shareholders of record on May 10th.
I feel kind of bad taking shares from someone down here but someone's got to buy them. It might as well be me.
The actual share price is still in the 34.70's range and should continue to go up to the 38's soon enough.
This company is just getting warmed up!
Is the sp down this AM to 33.19 because of the dividend payment to unit holders?
It just seemed to magically drop from 34.70's without any trading.
You just can't underestimate these shorties.
They still have a lot of powder, but I love to see them using ammo every day.
Eventually, the siege is better withstood on the long side!
I can wait
I sold my entire position yesterday at the 12.30 hump.
I will look to re-enter lower next week!
They did it again.
2.45 all day then painted to 2.38 at the close.
I don't think it has much of an effect any more.
Most of us are holding our shares long so good luck with that strategy.
I know.
Just awesome!!!
What an amazing distribution.
This will only get better with time and the availability of cheaper crude!
I'm looking forward to the next quarter.
Thanks for posting.
I picked up some more today
Thanks!
Just awesome!
I fully agree!
I do believe this is mostly manipulation by the short interest here. I also agree that they would love to get some of our shares at these ridiculous prices.
I have plenty of time to wait this out tho!
This is a great company with an outstanding product already approved and more in the pipeline.
I think it will take two quarters before we see the ship start the slow lumbering turn that is inevitable!
Started a position here today at 12.15
It should run into June.
On line gaming will be the game changer for this sector!
Awesome. Here we go!!!
Navidea Biopharmaceuticals Announces the U.S. Launch of Lymphoseek(R)
- First new lymphatic mapping drug approved in more than 30 years -
DUBLIN, Ohio, May 01, 2013 (BUSINESS WIRE) -- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on the development and commercialization of precision diagnostic radiopharmaceuticals, today announced the U.S. launch of Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection for use in lymphatic mapping procedures that are performed to help in the diagnostic evaluation of potential cancer spread for patients with breast cancer and melanoma. Lymphoseek was approved by the U.S. Food and Drug Administration (FDA) in March 2013.
As part of Navidea's U.S. distribution partnership, Cardinal Health is responsible for the sale and distribution of Lymphoseek to health care professionals through its existing network of nuclear pharmacies. Navidea is working closely with the company in all commercial activities and medical education programs for Lymphoseek.
"Commercialization of Lymphoseek in the U.S. marks a pivotal milestone for Navidea, and we are pleased to deliver this innovative diagnostic imaging agent to patients with breast cancer and melanoma, as we help advance the field of precision diagnostics," said Dr. Mark Pykett, Navidea's President and CEO. "With Cardinal Health's extensive reach and pre-eminent radiopharmacy network, combined with our own medical education activities now underway to engage target physician groups, we expect to begin driving optimal adoption of Lymphoseek throughout the U.S."
"We are very enthusiastic about exclusively supplying Lymphoseek through our more than 140 U.S. nuclear pharmacies at a time when lymphatic mapping continues to grow in importance for the diagnostic evaluation of cancer patients," said Sandra Wisniewski, Vice President of Marketing and Business Development for Cardinal Health Nuclear Pharmacy Services. "Through our collaborative efforts with Navidea, we have completed a comprehensive range of training and education programs and have a full portfolio of commercial tools to support a successful Lymphoseek commercialization."
Lymphoseek has been priced at $300 per patient procedure. Navidea has been working to ensure fair and equitable reimbursement for lymphatic mapping procedures using Lymphoseek. In the case of Medicare, Navidea believes these procedures are currently reimbursable under established codes, and expects to apply for and receive a unique pass-through code for Lymphoseek within a few months. Navidea and Cardinal Health will provide information and support to providers and payers to ensure that they can secure formulary status and appropriate payment.
According to the American Cancer Society, approximately 232,000 new cases of breast cancer and 77,000 new cases of melanoma are expected to be diagnosed in the United States in 2013. One of the procedures used by physicians to help in the diagnostic evaluation of breast cancer and melanoma is lymphatic mapping. Lymphatic mapping is a widely used procedure in which lymph nodes that may contain tumor metastases are identified and biopsied to determine if cancer has spread beyond the primary tumor. Navidea estimates that lymphatic mapping is utilized in approximately 70% of these patients each year in the United States.
Conference Call for Investors
Navidea Biopharmaceuticals will host a conference call for investors, today at 8:30 a.m. EDT to discuss the Lymphoseek launch. Conference call dial-in information is included below.
We are not very far from where we fell to after the CRL in the Fall.
This is very difficult to understand with an APPROVED product and plenty of upside!
Why are we not climbing steadily?
I bought another 5000 shares on that huge dip!
Yes. Hopefully some of the shorts will take these dips as an opportunity to start covering?
This would have to be one of the worst possible stocks to want to short.
The drugs work and the company is partnered with a giant in Cardinal.
Europe info is any day now and sales will soon be coming in on Lymphoseek which WAS approved by the FDA.
Certainly, there must be better stocks out there to bet against?
Some folks are getting out today before the FDA decision.
Good luck to all those holding through approval.
I left a toe in the water here only.
Just picked up some more sub 16